Study used blood test to identify distinct molecular signatures of disease; paves the way to precision medicine for cystic fibrosis
Researchers at Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago, and colleagues, used a blood test and microarray technology to identify distinct molecular signatures in children with cystic fibrosis. These patterns of gene expression ultimately could help predict disease severity and treatment response, and lead to therapies tailored to each patient’s precise biology. Findings were published in Physiological Genomics.
“Our findings pave the way to precision medicine for cystic fibrosis patients, eventually helping us match treatment to each patient’s unique genomic pattern of disease,” says lead author Hara Levy, MD, MMSc, from Manne Research Institute at Lurie Children’s, who is an Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine. “Our study was the first to identify molecular signatures of cystic fibrosis from a blood test taken during a routine clinic visit, giving us a baseline. Greater understanding of these molecular signatures may lead to unique molecular markers that could help us intervene earlier to changes in a patient’s inflammatory response to airway infection or pancreatic function, allowing us to provide more focused treatment. It would be a huge improvement over the one-size-fits-all treatment approach we currently have for patients with cystic fibrosis.”
To identify baseline molecular signatures in cystic fibrosis, Dr. Levy’s lab obtained genomic information from patients’ blood samples using cutting-edge technologies such as Affymetric array and Illumina MiSeq. The team then merged this genomic information with each individual’s clinical history gathered from electronic medical records. They compared this snapshot of patient-specific data with healthy controls. Their study provides strong evidence for distinct molecular signatures in cystic fibrosis patients that correlate with clinical outcomes.
Cystic fibrosis is a progressive genetic disease that damages multiple organs, including the lungs and pancreas. Currently, the average predicted survival is 47 years. Although cystic fibrosis is caused by dysfunction of a single gene (CFTR) and treatment that targets CFTR mutations is available, the relationships between the abnormal gene product, development of inflammation and disease progression are not fully understood. This limits the ability to predict a patient’s clinical course, provide individualized treatment and rapidly monitor treatment response.
For example, it is not clear why patients with cystic fibrosis are susceptible to chronic lung infections, since they are considered to have a functional immune system.
“We are now trying to discover why patients with cystic fibrosis become infected so easily,” says Dr. Levy. “We are taking a closer look at the immune cells that make up many of the molecular signatures we found in cystic fibrosis.”
More study is needed before precision medicine for cystic fibrosis reaches the clinic.
“With more research, a blood test to gather genomic specifics of each patient’s disease might be available in the clinic within the next five years,” says Dr. Levy. “Precision medicine will revolutionize care for cystic fibrosis patients.”
The Latest on: Cystic fibrosis
via Google News
The Latest on: Cystic fibrosis
- Bacteria-infecting viruses exacerbate chronic infections in cystic fibrosis on April 18, 2019 at 2:45 am
A study of samples from 92 patients with cystic fibrosis (CF) has revealed that certain bacteriophages - viruses that infect bacteria - worsen the severity of bacterial infections associated with ... […]
- Irish family faces deportation after son diagnosed with cystic fibrosis on April 18, 2019 at 12:13 am
An Irish family, who has been living in Australia for almost 10 years, is facing deportation after their son was diagnosed with cystic fibrosis and deemed a "burden" on the country's health system. ... […]
- Cystic Fibrosis Market 2019 by Treatment Method, Value, Size, Industry Dynamics, Regions, Top Companies Analysis and Forecast to 2023 on April 17, 2019 at 7:07 pm
Apr 17, 2019 (AB Digital via COMTEX) -- Leading players in the global cystic fibrosis market include Vertex Pharmaceuticals, AbbVie, Novartis, Pharmaxis, Forest Laboratories, Chiesi Farmaceutici, ... […]
- Cytomegalovirus May Speed Disease Progression in Cystic Fibrosis on April 17, 2019 at 2:58 pm
Patients with cystic fibrosis who had cytomegalovirus had earlier times to lung transplant referral and reaching final stages of disease. Researchers have identified a potential explanation for why ... […]
- A virus we thought was harmless to humans may worsen cystic fibrosis on April 17, 2019 at 11:05 am
People with cystic fibrosis may experience more severe bacterial infections if they carry a certain type of virus – even though the virus actually targets bacteria. The so-called filamentous ... […]
- Laps for Landon raises $7,000 for cystic fibrosis on April 17, 2019 at 8:07 am
The wind carried music across Welch Stadium, beckoning all to come support raising cystic fibrosis awareness. More than 400 Emporians of all ages, as well as members of other communities in the region ... […]
- Gene editing could cure cystic fibrosis before birth, study suggests on April 17, 2019 at 7:00 am
Scientists may soon be able to gene-edit horrible lung diseases like cystic fibrosis out of the human genome, a new study in mice suggests. The CRISPR gene editing tool allows scientists to ... […]
- New test could lead to personalized treatments for cystic fibrosis on April 17, 2019 at 5:59 am
Cystic fibrosis is a devastating disease caused by mutations in a specific gene, known as the CFTR gene. But not everyone with cystic fibrosis has the same symptoms or responds to drug treatments ... […]
- Agony of cystic fibrosis sufferer, 29, who was given a new lease on life thanks to a double lung transplant but contracted a virus from her donor on April 17, 2019 at 5:27 am
A 29-year-old Massachusetts woman who received a double long transplant to treat her cystic fibrosis is recovering after contracting a virus from her donor. Rima Manomaitis, of Pepperell, has been ... […]
- Bowman, Cotter win Cystic Fibrosis benefit tourney on April 16, 2019 at 11:39 am
Ty Bowman and Verlin Cotter hold their trophies after winning the 34th annual Cystic Fibrosis Benefit Bass Tournament on Norfork Lake. Pictured with Bowman and Cotter are tournament director Dan ... […]
via Bing News